Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2026 08:12 ET | Source: Sparian Biosciences, Inc

Sparian Biosciences Announces Initiation of Phase 1 Clinical Trial of SBS-147 Next Generation Arylepoxamide Agonist for the Treatment of Pain Funded by a $15M NIH Grant

Sparian Biosciences initiates a phase 1 clinical trial of SBS-147, its next generation arylepoxamide receptor (AEAr) agonist for acute and chronic pain.